SPEVIGO (Boehringer Ingelheim Pty Ltd)
Product name
SPEVIGO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
186 (255 working days)
Active ingredients
spesolimab
Registration type
EOI
Indication
SPEVIGO is indicated for the treatment of generalised pustular psoriasis (GPP), including treatment and prevention of flares, in adults and adolescents from 12 years of age and weighing at least 40 kg.